Novacyt S.A.
PAR: ALNOV.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Lyn Dafydd Rees
- Employees
- 234
- Headquarters
- Le Vésinet, France
- IPO year
- 2012
- Market cap
- €39.0M
- Website
- https://www.novacyt.com
Loading ALNOV…
Loading profile data…Frequently asked questions about ALNOV
What does Novacyt S.A. (ALNOV.PA) do?
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-...
Where does ALNOV.PA trade?
Novacyt S.A. (ALNOV.PA) trades on the Euronext Paris.
What sector is ALNOV.PA in?
Novacyt S.A. (ALNOV.PA) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Novacyt S.A.?
Lyn Dafydd Rees is the chief executive officer of Novacyt S.A. (ALNOV.PA).
Where is Novacyt S.A. headquartered?
Novacyt S.A. is headquartered in France.
Does ALNOV.PA pay a dividend?
Novacyt S.A. (ALNOV.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALNOV.PA go public?
Novacyt S.A. (ALNOV.PA) completed its initial public offering in 2012.